Pirfenidone is the only medicine approved worldwide for IPF.

Pirfenidone is marketed by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.

View Pipeline

ACTIMMUNE (Interferon gamma-1b)

For additional information on Actimmune® including full
prescribing information, please go to www.actimmune.com.

More about Actimmune®

ERS Research Award on IPF

Award for a young investigator. Application deadline for 2012: February 23, 2012. Learn More



Ascend Clinical Trial

For information on the ASCEND Phase 3 study of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) please visit clinicaltrials.gov.